WAT - Earnings call transcript Q3 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. Welcome to the Waters Corporation Third Quarter 2018 Financial Results Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference call begins. This conference call is being recorded. If anyone have objections, please disconnect at this time. pleasure the my Mr. over now is to call turn to It Brokmeier, Relations. of Bryan Investor Head ahead, go Please sir.

Bryan Brokmeier

call. operator. welcome Corporation conference to you, the Thank Good Waters third morning, quarter everyone, and earnings

cautionary Before language. we will begin, cover I the

various During the conference In performance regarding this future course particular, financial we events future the guidance statements forward-looking regarding will or possible you are call, future of differ statements we fourth of make Company. income predictions will quarter for and that of all We XXXX. materially. results actual such statement that the caution only may and events the full-year results provide Company or

you calls plan by next not providing except regularly earnings We Annual detailed further discussion to for the on year statement itself or regarding XX, a future to do guidance release We the and webcast conference The income actual scheduled caption, XXXX. that obligate currently Form ended the risks fiscal not performance included In and caution and XXXX. release Factors, December the contingencies cautionary planned our and our possible that predictions. this release is results update differ under update significantly this and commit predictions to webcasts. For during language present does Part in Company Report some cause earnings X-K. press Risk quarterly our X our of XX-K could from the XX, of see morning's expectations, call for January

increasing references included mostly operations, or as earnings of release. results otherwise, such In issued our GAAP are we Unless refer discussions exclude today's comparison morning. in the to Adjusted Financials financial to the certain pro forma say titled decreasing financial quarter Non-GAAP measures. GAAP outlined the may comparable non-GAAP call, and our results A items measures referring the in which the of we impact the non-GAAP XXXX. to this press to this schedule year in of morning's Reconciliation to third to During reconciliation of of we measures attached those quarterly release to results, be are press will fiscal directly

including In all given on addition, currency call basis. ranges growth today's on a rates unless say given growth are comparable year-over-year revenue revenue otherwise, constant we

Now Chief call I turn Officer, would like the to over Chairman to Chris? O'Connell. Waters' and Chris Executive

Christopher O'Connell

is morning, Thank today. us for Financial Thanks, me Along everyone. Waters' Officer. Chief joining good Brokmeier, Bryan, call joining with Sherry and you on this Bryan Buck, morning's

as commentary overview details then call, quarter financial today's fourth provide results, on I some XXXX financial as third our operating outlook. business. will During Sherry our broader on provide quarter comments results well an full-year will and of in our and our review

up our X% then reviewing both year-to-date the X% phone quarter grew quarter for and the and adjusted and questions. open third We financial revenues lines year-to-date. take will your Briefly highlights, per our to earnings for grew X% share

our with to While third on shared the we call. July sales our significant continue make that growth our initiatives, we during key below came in you strategic progress expectations quarter

I give the slowly. market. China bit India expected in will and progressing improvement recovery Pharma, weaker and spots, QX normalized two you growth saw on had is of soft with Furthermore, color we start the performance Pharma strength in in To more While Instruments. see than European a TA line a our we areas: continue to product Instruments key nice TA in U.S

order and European, with quarter. shipments was to expected this TA timing year-to-date the U.S., slower of in in the in growth product the was and a to year-to-date, sales That had sales X% While in said, due line underlying QX customers. order despite certain Chinese than line TA quarter soft growth the trends was encouraging

which and early backdrop. is long-term be new economic is We about innings solid a to product by cycle product of near and thermal line, the in supported and of the analysis TA continue excited prospects major the

in the spending in Pharma top within end of the with during was pressure XXXX. the we Europe growth the European quarter our dynamics into in Our customers by among saw challenged U.S remains pharma end improvement an quarter, pharmaceutical heading market. tempered uncertain in big Though

to On during customers the quarter. our picked positive the side, in sales the U.S pharmaceutical up meaningfully

by Outside U.S., QX China that with We continue we the are strong expectations to we and of the excel Furthermore, our teens assume LC remain stable. with largest trend. Instrument pharma demand encouraged a improved our worldwide U.S of spending the are in customers continuation in mid growth. seeing that

briefly are top expected the results despite pleased the the Looking with P&L, line growth. than earnings solid at we slower

While driven growth drove the disciplined our modest future to margin a our year-over-year in management China level, growth operating business modest organic and starting clinical closer applications. in U.S., sales category investing in offset into at pharmaceutical markets that we our market pickup earnings-per-share categories defined us sales enabling demonstrated aforementioned target. the expense through in with look expansion by Taking in third partially by a the quarter exceed a of to innovation, corporate review now, decline and the decline increased the Pharma double-digit X% at European broadly

performance. perform the customers weakness X% positioning see applications. environment the The in we're our investment continue which product particular our remain account feel pharma and Europe. markets pharmaceutical of our prior overall pharma against market large our molecule development. in customers and market up a sales are LC approximately long-term drug pipeline bio year global opportunities in our needs about we meet solid good remains pockets business. position, solid applications, growth to in for Importantly, to of We new of India outside on line and one-third based to ability to related our and of well positive molecule confident Year-to-date, in Sales these of

in softer of the Despite worldwide up were our demand our by customers. applications. analysis Third than remain quarter breadth as well offset expected quarter, and the positions Weakness pipeline and category environmental third X%. Sales X%. strong the we in safety partially food, more up research and chemical in strength softer materials characterization, the across characterization, and and by as by in academic category, chemical in biomedical increased material in includes growth product in the opportunities Year-to-date, fine confident our industrial with in Europe. applications food year-over-year, grew worldwide discovery Americas, the X% research from was by to Asia category these and environmental strength governmental category growth markets. was governmental our our both than academic among food, offset pharmaceutical Year-to-date, industrial sales X% quarter and sales which environmental and markets led

performance will corporate I sales geography the by our Next at level. review

modest largest growth by region our China was the India. Asia, double-digit our quarter within partially China with line. in chemical revenue TA up in robust remains markets, terms strong in in fine in offset Demand Instruments growth in product growth pharma, softness X% and of and food, and

the X% U.S Turning overall the in were sales grew to Americas, while sales flat. the quarter, within

offset as and biomedical line. product clinical sales driven during unexpected growth, Canada softness mentioned customer from solid Europe, offset Although in in these by by the before, was softness were weakness were were applications Latin base TA research. our lower-than-expected the quarter we region applications U.S In growth in by industrial by was regions in in our offset the pharmaceutical clinical X% Pharma that large U.S. America strong, sales and Increasing in Instruments down strength pharma,

LC the Finally, for within and continues Waters flat momentum I the overall our sales underlying will we Meanwhile, strength standalone and Acuity regulated geographies, brands. HPLC Plus, LC, largely position third of TA line sales branded Acuity system, was Within review product launched the growth the were reinforcing which build to Alliance with in earlier the Bio markets. our the by dynamics Waters strong Instrument across instruments. in all in instrument quarter in our chromatography driven with strength growth year. Arc further

year compared modestly saw product to spec encouragingly we spec mass high our and the resolution Our line half portfolio. mass of first in stabilization the improved

the Our spec TQ-XS. sold mass over by Xevo has year, the core highlighted tandem last quad well portfolio

initially with beginning shift labs. testing where the shipping significant There of from TQ-GC Asia, and newly to During target the government began established is legacy just safety QDa food safety quarter, we opportunity DART labs both China market. in particularly Xevo which testing independent the LiveID, and to will food system in is

in Columns by in the diagnostics. This saw Pharma, clinical Waters demand serving recurring excited total encouraged the the and our reliable We recently and it BioResolve an announced clinical reflect the next of the also about represent approximately service antibody reversed-phase use XX strong which and needs XX% of recurring by Bioseparation and the general growth high is kits of particular, of open proven revenues branded Waters' on laboratories. grew experience integrated system newly precision of columns. our UPLC generation RenataDX our bench-top screening and strength of newborn launch are sales, are global fully we launched for general years chemistries system We monoclonal In application robust quarter. X% and columns. in revenues, service driven diagnostic throughput builds strong with screening the businesses platform combination performance for

-- service sales to for Instrument by Turning me, systems product increased X%, quarter. and X TA our TA sales increased in decreased X% line, increased the sales by third excuse X%.

thermal our ElectroForce strength in and sales in our lines. product Softer microcalorimetry rheology, analyzers offset

products. in few discipline give and highlighted strong earnings our summary, expectations. In a operational strong and consistent confidence year-to-date some has product uneven we That we’ve categories. earlier, our TA portfolio our geographies the said, strength been As position order due key exceeded in our continuing dynamics growth, unexpected leading to and product of maintained market growth us

products of against by a our significant that transform several the headlined to progress growth We generation series efforts beginning making past market. deliver process next is to are years over our initiatives, innovation to our

comments capital creation remain deployment, value I focused point reiterate additional we steadfastly executing some on would our like Before to that innovation model. five on on and

markets. a previously with have position we seeking and for operating value to focused differentiated Four, Two, one, create strategy capital team. driven innovation. and performance As organic and in by five, operational growth improvement. management shareholder attractive oriented highly opportunity culture a holding continuous being allocator, Three, by aim structurally clear disciplined communicated, executing a we

We enhance our is developed proactively overall transformation innovation technologies are innovation year-to-date and throughout innovations, to in R&D pipeline. strengthen resulting external product and a increasingly with select our to in There X%. new these excitement continue of internal products. the and evaluating our Waters we about portfolio prioritize organic invest organically our enhancements lot product growing To augment investments

focus has stepped and team benefits In line of the up and and well the years XXX. such see we as have now UPLC RenataDX products Acuity the we LiveID, of Series, management the efforts. the to new with QDa beginning pace Our these system as Acuity development the over XXXX, product the launched Arc several are product Bio as our System, additions screening to Plus chemistry Dart DMA Xevo the the TA TQGC, past numerous

greater these seen XXXX realize in them products from beyond. new successful have we launches, to revenue While contribution and a expect

we Looking major are bench-top program. BioTOF ahead first that excited the about mass This steps to new routine for by integrated LCMS is of a a our XXXX, monitoring highlighted product industry's cycle, biopharmaceutical platform begin system and first release additional number of the will spectrometry-based launches testing.

to of the bench, range workflow a we users to deployment deployment, capital Our and/or to capital process U.S cash, to efficiently. make strategy decision product analytical multiple acquire a to tax needed provided system streamline sample efficient that balance following system with but our diverse that event result, is reform. our our need to have research grade of spec a enable and biopharmaceutical challenge single will concluded This This enough within work of as to more compact to XXXX. more process routine decisions is operators reproducible deliver result delivers seminal to mass quantify put new Shifting existing analysis. customers a we using performance sheet an more and in a global This review monitor powerful tax enough a extensive who supporting employ sit to Waters to has high-end systems. data on access attributes obtain intend

interaction To target enhanced on on that ratio EBITDA approximately to recently Day structure plan our further to I'm further topics critical deeper Investor insights provide your like save net will quarter on on a debt an program forward Sherry With be with accelerate management an pass deployment in in the to and announce share event presentations, XX, please initiatives, further I for for I host review forum, York featuring Buck a into and call capital details buyback the will forthcoming, I opportunity New will you City. in-depth include in Sherry More with our look of February We -- near-term and XXXX morning deeper growth that, comments. over go and financials. capital of date with a third which details will the her to Q&A, to provide would investors X.Xx. look management key calendars. we for the pleased these Sherry? but informal about that to engaging team. Waters of the

Sherry Buck

everyone. of approximately million, good X% recorded sales $XXX In markets growth currency. you, sales X%. resulting our and governmental X% markets the X%, translation into sales as decreased quarter, increase approximately our pharmaceutical quarter, net industrial Thank by in and into we both of sales morning, In in Chris, and X% an constant Currency growth grew academic and reported. the sales grew third

and represents the products service instrument were sales revenue recurring our at flat. a chemistry while combination quarter, grew line Looking of precision in revenue growth, X% product which

no we calendar day fourth the one XXXX. during is sales quarter, were by flat in in days there to products of branded the TA grew branded XXXX products X%, TA's difference instrument number As of instrumentation the decreased noted but related sales quarter, sales grew X%, product down additional was and while LC and sales compared and LCMS third year-over-year to Breaking system of there quarter platform last Waters calendar services combined sales X%. further,

grew which Our revenues, total both and recurring by includes TA Waters products X%.

European up were rates growth down led constant were by with in currency sales sales and and sales third our X%, in Americas on the the at flat China. U.S. sales XX% Asia the were Looking X% in basis, a geographically quarter in growth up in X%

to performance was like quarter quarters would margin I non-GAAP versus third XX.X% both the Now comment XXXX our Gross on and financial third prior the for of year. XXXX.

third our benefiting expectation as approximately impact reflects effective a basis down investments year. prior line operating year-over-year, and the constant return QX versus the was by capital interest we call. increased X% up operating our down, basis. decreased expenses million of framework of the expense the Net well tax as our In currency rates our year was net rate from on $X a operating approximately growth from points in as P&L, $X discussed U.S deployment earnings X% reform prior XXX on basis foreign reduced by tax currency quarter, translation levels Moving quarter that part was expense in and XX.X%, million, on higher reported which with XXXX of debt the

of Our shares in average share million XX.X count in came than share at third is lower of shares, million quarter approximately program. effect a the This repurchase ongoing year. last net X.X our

this per we year. versus issued to to earnings release for Our On of share $X.XX found reconciliation non-GAAP comparison the to GAAP morning. $X.XX were share up were earnings in our of A per a X% the can last last that non-GAAP earnings third in diluted earnings basis, press a year. GAAP be a $X.XX our a $X.XX quarter

of related deployment funding Turning results and the million $X.XX In plan, activities. free related million our quarter, sales cash less the cash our were sheet, Taunton items. define $X $XX our $X.XX this would reform free to as $X Chemistry free payments, came and converted third I in from third in dollar into cash related and a $X in summarize the of Excluded to million free and expenditures. quarter excluding each pension third flow flow international funding for operations to Precision U.S results In flow cash tax expenditures year-to-date. investment certain XXXX, and Operation. million special after at free balance flow million of quarter cash $XXX like flow, capital of cash to the capital We from capital

shares I capital billion cash terms $X.X million investments and of in $XXX flexibility; strength repurchased $XXX to free the and of approximately with second, billion our sheet with of X.X activities some capital In we for communications, during structure. returning allocation X.X shareholders related debt we short-term a million. in like deployment to cash quarter, Year-to-date, our to on to $X.X million in resulted and deployment of prioritized capital shares flow business; and purchased These the third, capital capital our our net in three the balance million. of invest stock markets. Number prior Consistent additional million. end common provide the our along quarter, $XXX near-term one, cash would maintain return capital and of at for balance have position resulting comments we sheet shareholders.

was we which We to committed U.S tax from repurchase review $X.X our In following first share provided capital reform continue program with a to of step XXXX, tax be new cash shareholders. us billion, deployment cash. global our the returning access to comprehensive to more efficient that April of announced

we’ve Directors up have ability review on maintaining the repurchase pace to comments, capital structure continued and program, that flexibility to business organic of inorganic our Chris's the financial the with to concluded through in Following and opportunities. but also share our of our earlier Board invest accelerate the both we’ve

Towards to fourth bring to This stock. repurchases about share full-year $XXX billion. of that during common plan XXXX we quarter the continue of our anticipate share buying million $X.X and repurchases back would our acceleration the end, approximately

plan to near-term sheet of program As balance share to a for EBITDA forward a utilize to robust net XXXX, capital we to support look debt our ratio approximately structure XXXX. repurchase we with X.Xx

which was increased this seasonal last in our prior details In quarter quarter, approximately receivable, in to in more plans in at days by Investor million line increased of quarter, We days third $XX outstanding XX patterns. up typical the the earnings with will February inventories from year year. during the our provide comparison XXXX. QX our days to sales quarter, Day Accounts XXXX of call and XX

comment XXXX would full-year the our of the As we to look forward guidance. like to on I year, balance

outlook continued prior These assumed guidance our XX.X% growth X% X% growth to Our and recurring increase X%. demand guidance our point. sales year of growth translation is to percentage unchanged Gross markets about end margin for growth XX%. At by of for currency guidance constant and dynamics current to our XXXX range assumes to is support at global continued currency rates, sales from XXXX from revenue. full-year in X%, one the

is expense below Our plan that operating for continue the managing rate is to growth growth a at our sales full-year rate.

to from in expected first repaid debt million operating expense below quarters the line, $XX million. prior approximately of income that of the the This $XX guidance not year. Moving assumes the the XXXX is interest net during be three reborrowed of is our course

effective tax to rate in full-year XX% Our be range estimated to is the XX%. of

in quarter of assumes fourth in guidance on remarks outstanding. approximately count share continued the acceleration Our $X.XX our be neutral, expected in my share earlier will diluted per diluted earnings of average this foreign in range are result shares per share with full-year growth prior million of to currency current the share non-GAAP guidance. from as is Rolling to on all to of which $X.XX. is $X a impact our earnings full-year projected to prior be consistent range together At repurchases guidance mentioned the XX $X.XX an XXXX and fully rates, basis,

our year-to-date sales a expected the translation is decrease expect growth Looking impact few in range by moderate to fourth fourth fourth now guidance points. which quarter fourth with constant approximate factors an a Therefore, rates, these performance currency comments. X a estimate quarter current $X.XX, from at currency growth the we expenses, share rates. currency continuation to X% Combining in the Chris? to sales quarter in summary $X.XX X quarter. of we diluted to earnings of percentage Chris X% at X% trends. assumes line At today's translation per negative make of our XXXX, non-GAAP will increase top assumes

Christopher O'Connell

discipline you, priority markets technology new earnings our health while of we’ve position question-and-answer updating you maintained XXXX, our through categories. will our Great. early remain strong Sherry. I we’ve and To expectations, unexpected program. look exceeded in three competitive seen remaining Thank through the that, With said, during and geographies and significant some the we That to and delivering bumps the few our Furthermore, categories. we session. our in QX strong innovation forward first key recap, pipeline further focused quarters of on end operational a in steadfastly now enhanced XXXX. our in begin confident product

please contact And to you are limit to always one relations one As the after yourself questions, not follow-up. question to we able please have get call. and the additional everyone's team if Waters questions, investor Operator?

Operator

We will Instructions] Stanley. from response take you. Beuchaw, Thank first our Morgan [Operator Steve

Your line open. is

Steve Beuchaw

Hi, thanks for time here. good the morning and

totality the Pharma we help sort you try in think compare XXXX I to historical is think growth that to the think, for plus, and mid just generally Waters. of if it norm which of Chris, of would single-digit about bellwether

what about year big you’ve can headwinds. we Over are the year, And couple from here? a headwind? you you this as of one-off know, what you acceleration course of how this one-off tell a had How is summarize, of, us what products drivers would new think

Christopher O'Connell

has has the can course a we've deeper for is bit pattern consistent and X% on India point of road basis. Yes. a lines. we're characterized or think geographies seen a the in headwind the we’ve which evolved the some the headed down with obviously a has Obviously, year down over the we way the year well, of working couple concerns, on And Thanks, little seen the broader it into key as knocked India, GST year-over-year year tax economic by year-ago has some been or fully to implementation our rupee not a expected in throughout base issues customer and what that growth product was through in go more Steve, a we the question. and bumps most I you shown the

out Europe been course That outside variety political we’ve contributed some really very Pharma, well. slow in headwind. had the closely. of consistent which some as that, said, in tailwind has China's started India positives issues including probably U.S market consistent so, to uncertainty related and of the which factors And quarter. that of quite have in in most improving being of pockets seen some particularly we’ve we’ve a the And a we the that we that thing year that is the as been watch over real saw

And on really of two just areas. execution the and the and really so in the at than steadfastly and consider tried in the start mass non-incremental launches XXXX, look some remain innovation, spec incremental showing their to seen what should back some your of multiyear combined -- product half as totality a other high exciting innovation cycle. type the year on ahead those is we’ve and entrants look coming This BioTOF I launches promise point year, prior I to XXXX, of years in in of the -- course focused what year, resolution product we we've as more particularly in have with of we new program,

I that's we’ve in for So, outlook We’ve some remain line we very 'XX, long-term. of bumps from -- wavered the not the core our we're confident really geography strategy. product and worked business that. think the And in as through

Steve Beuchaw

that And in you. Thank will give you And just embedding, to assumption you then improved India more quickly us called in sense there? back you you follow-up behind was XQ? give what you’re whether on any on the And in Pharma any in for out can a queue. color for of us a Can trends points in Europe slowness made. I get couple

Christopher O'Connell

Sure.

the as we've tend buyers. years know has that I India. it's impacted coming demand the for of course political patient degree is up pretty of some what for devaluation. India some In long in India, environment our We be moderated to rupee year, observed over time India next in like elections a that with by and a next clear terms the moderation see said, reflecting building. of is market the been Indian year become round of great you the in customers pent-up and over have do outlook But we more uncertainty the economic part

expected. we more it's just we remain come back India so will than -- come believe We very back slowly And focused.

And not terms of a so in in our bounce we're huge assuming QX guidance.

the assuming question? what more we’ve of our of are overall QX the of consistent that And continuation reflecting we’ve the year outlook throughout We part throughout of that's trend seen a continuation Sherry's with and what last was on the comments the the year. seen

Steve Beuchaw

believe actually on looking relative you it Just that for Europe? I out? in curios considering is why trend, clarity to called catalyst different particularly was growth but trend the that to the the comp mean what for you change the wasn't

Christopher O'Connell

a normalization. like on there are strong comments, and we Turkey customer a Europe year we expect a said did have performance very reflects are franchise was related probably rolls softer, situation resolution And at some we a been but watching more double-digit it did our don't necessarily incremental market persevere. And, the a factors some anticipate closer sort got Europe quarter is see uncertainty. other ahead that we base certainly, big a And to bit I that of some of seen double-digit to we hopefully comp like near-term to in growth some But Brexit country prior of of look term, to has chill in in strong tough The significant there prepared obviously on closely. comps, positive as year. look certainly bounce certainly, we strong Pharma probably sentiment. expect our and we effects we Europe my Well, countries with I as particularly have but some we specific dynamics, the in have a put has certainly XXXX. XXXX Europe, if trend a with we’ve believe Western we third in overall guess, next bit specific immediate with

Steve Beuchaw

Thanks much, Chris.

Christopher O'Connell

Yes.

Operator

you. Thank

Our JPMorgan. Peterson be next question will from of Tycho

open. is line Your

Tycho Peterson

in other out, so on hone is I Chris, to want soft Thanks. few called spot the you industrial. a of

side the talked a of Obviously, order been book headlines industrial the shipments said a including point about bit have I you You not the think encouraging timing was data better. and more there little very the from few today.

I So coming quarter? confidence really of is a that timing issue you the gives this what out guess

Christopher O'Connell

was but line. a product growth a where have to really certain process specifically China interestingly comments in with that in shipments, in quarters end see including Tycho. sale. in And you we typically very of the case, QX a the happened wanted but timing seen to, there Thanks, order shipments referred that with encouraging. was an elongated much in got provide Yes. kind to a for of orders different TA order couple we around delayed of to I some in the enough we is China, we’ve quarter, growth this of Instrument made year. TA TA as saw consistent we The few But dynamic the just to the what don't regions, that it now all order It color which this was mix

possibly back confidence the TA we’ve will a in effect QX. think coming. quarter I inventory linked order of robust with situation TA hand we’ve The in discovery overall towards trade franchise the to from have launches to as had much in what a expect China, on in some broader in global and that and lot the we And core standpoint, we more a seen we just we’ve of new product terms an that different of franchise slightly standpoint, mix dynamics Instruments headed position certainly our Chinese in saw has QX. in bounce terms of an that normalize the but we from

Tycho Peterson

prepared you well? in you called similarly, And a your out then that softness, clinical the few as can times Okay. comments comment on

Christopher O'Connell

the of year particularly half, saw a a its what is big the pretty a strong nicely clinical of first on a was just in Yes, quarter clinical year. year-to-date. was weaker slightly Europe had last activity of what top and comp first up in We and Sure. half lot really actually

and parts of clinical to due have IVD weakness pain bigger in remarks, space, but as has a clinical in be like the picture been mentioned solid back focused system. my comps where particularly to in into position new in year-to-date stepping the that a the a of management the RenataDX, and diagnostics, business screening and -- product and And lumpy we’ve business. there certain coming business, the general policy at tend such that that year in category reimbursement some clinical, next Some in continue shifts had we’ve generation to of is looking category, again use I which the we we clinical

Tycho Peterson

then thinking discipline this environment I’m highlighted if curious since actions how any well. you're about on as operational one And OpEx? just or cost you Okay. last just you’re one in that accelerating

Christopher O'Connell

that would monitor operating continue I closely. we to very expenses our say

any very will unusual the to some and top certainly the on a those. in And over been to like standpoint. haven't We been in a we taken operator the delivered despite bumps are of more know cost these saw operating in on actions. bumps disciplined spending of line of some the has year as I line have bottom We’ve our as the in focused road course headcount conservative But some -- from line. continue you remarks, on Waters the on of top stay always pleased said we the the expansion

Tycho Peterson

Thank you. Okay.

Christopher O'Connell

Thanks.

Operator

you. Thank

question Daniel of is Brennan Our UBS. next from

is open. line Your

Daniel Brennan

Hey, Chris. Thank you.

So biopharma hoping just a I was revisit to for moment. European maybe

terms the in Turkey is little European us what the to give grow more U.K what of actually really more it called like And in biopharma it's just you extra out. and there you or could shrink business? sounds detail related -- Just did

of you’re I’m So, Europe and color, across I a bit broadly more looking what for biopharma the customers? more guess, seeing kind with just little

Christopher O'Connell

We, we our Europe did quarter Europe in strength saw Pharma much by the the we our of was we trade very comps in in before, in report which and generally. Yes, because and in that -- in we've which Since since some and that biopharma But offset in U.S. bag a Pharma, particular robust related of by U.S the past in were really some the there that were really had, to a biopharma I quarter in offset general biopharma on really mixed it's that some a or strength of weakness some generally, mentioned weak strong chill class also U.S encouraging both growth seen two. clinical the quarter, the market bit research very we in see in particularly a bit biomedical as in and numbers biopharma.

is say, I and globally, themes a mixed bit the picture it of Dan, I mentioned. a reflects So of broader would some

Daniel Brennan

more India. And then on just one maybe

it kind the rupee So obviously of quarter, your modestly maybe and flagging in India but the there. sounds grew some uncertainty economic like

rate your viewpoint forward India watch of should see towards should if think you. So that Waters? maybe on we us and do a recovery growth other other? for kind Thank business you how going just can of about give the to signpost and is What think we you an Indian horizon the for

Christopher O'Connell

something Yes, watching we carefully. are sure. It's

a we the customers saw still can cycles. will focused that terms perk of buyers. the the demand in of revenues expect really have in moderated, very be particularly contribution tend in the the are rupee, lines customer long-term as underlying the trying mentioned not-too-distant long to me, really of of the become earlier confidence -- us seen confidence you team. customers with we it's be utilization market the and very India, that pronounced do the And steady recurring recurring they’re the because history point. go if technology. But We’ve of in are sort of as just in of believe in underlying underlying India. hopefully said, in it think lot India future. to there. volumes in management I the hopefully the the pent-up our some there at are instrument contribute as demand, And over our activity give But signposts, and as in watching reacceleration look ruby India tipping our We does We to we what some in which year-over-year -- stabilizes a pardon building, pretty confidence to and Indian see patient it that producing up point, India, for That trend the we sort the We side. as to relates in positive in patient we’ve staying measured revenues there as comps of in I the is as

Daniel Brennan

Thank Great. you.

Christopher O'Connell

you. Thank

Operator

you. Thank

be ISI. next question Evercore of from will Ross Muken Our

is open. line Your

Ross Muken

as which launches, address guess sort traditional you thinking I how you dynamic some where the some not noise in of spec. of performance? a to how sort been seeing? mass back were shared of couple of in the There of you guys. there competing used morning, about your and to markets we're your you And the a competitive I would are new product of going this has some of thinking the of to lot markets categories, the are sort key Good guess, stability is guess as around I around like. aggressively go in sort of But maybe particularly, shared sort dynamics of

Christopher O'Connell

bit we are a quarter our sure. times actually our near-term on before, Yes, before, half Like if to closer pipeline first I’ve third We’ve see I and direction we right products. little did as product reasonably I to is challenging a do the it. to very encouraging comp had new mass a XX forward Ross. line, a are looking point our Like and signs Thanks, product said feel in getting position we segment, mentioned a solid in some moving that mass and bounce well. look the year-over-year you high out, we like quad we robust spec said, as position core in really are mass But total and in there, a got in some many the we in spec. core you we and like late res of and improvement cycle product I saw spec modest as

res program, I’ve some do of in and BioTOF number near-term mass spec exciting we're broader have evaluation as system, a participated well of new the on which products we category. really demo in, example, and of high personally of well customer the phase into and For a the

the moving the Company direction. getting better. stable that reasonably feel it's important I product like an in near-term It's like feel hopefully said, right So and I and we the are in line for

Ross Muken

I what merits side, are remaining of allocation the like of biased capital on of And the years? X, of leverage. of to the as fairly up or fuel basis repurchase, X guys you purchases, repurchase sort were share other you the how sort the sort needs you of seems thinking over versus returns business next M&A the that more as about on technology to aggressive top line a take guess I the sort debating still and again are it you kind guess,

Christopher O'Connell

our Yes, and time a as spent that's a we’ve tax a discussing the lot very very for out, was reform of locked Sherry our pointed us flexibility, and were now changer. strong business game -- lot capital now because question, global say, total given of have terrific flows. on allocation, we’ve of sheet financial balance cash the We and Ross, beforehand a we're economics very unlocked and

sufficient walls allocation of to business, first, the plenty in invest mentioned, we are in in our innovation are, you what's have that in with to make with continue in cash small attributes. the incremental maintain growth innovation happening for capacity saw of more the invest we earlier the buyback all on Certainly financial headlined capacity to grow plus enhance business priorities and Prosolia-DESI of borrowing that, our our doing But certainly more as to retaining will cash to IP and through the hand, buyback, acquisition. feel to additions. capital we organic a Our work way I And put we towards to structure. right to considering capital expense. partially optimal year to now are work that and our flexibility scenario, in by fully time and cash the four And and very program a to any and our to deploy sure to deploy relative our we borrowing more close purposeful capital is sheet balance technology outside in capacity

Ross Muken

a Thanks lot.

Christopher O'Connell

you. Thank

Operator

Arias will Citigroup. next be from question Our of Dan

open. is line Your

Dan Arias

your much apologies doesn’t flush morning. try guide finish from of assume XQ end you Thanks. Europe? really fair good to way but might is year there it Pharma. might out if and into Chris, parse like Is you particularly, the the to any in of mentioned in way spend activity Hey, that the insight this, that Pharma that if you have XQ, feels

Christopher O'Connell

Yes.

are earlier, not a U.S., as expect that Where we the of address good and the we on geography-by-geography that I type we I major hand, that, no, where and I a spending looking on But continue mentioned, a Pharma mentioned end activity. in other something little in forecasting showed year. in the in Sherry that’s the and that to it. didn't I basis. flush. as directly would I some of year-end from our question our The continuation flush say, just of Certainly, forecast quarter more reiterate Europe conservative in terms a really happens we what are on to relative I a as ought trends uptick at see we would encouraging are think a the QX, say that we sit of today, third towards outlook on

year set India. geographies end of U.S. So more probably and conservative overall, strength for China Europe the balanced on assumptions like of the a and in with purchasing outlook I we’ve think, and

characterize So it bit of assumption. the I would as road middle a a of

Dan Arias

also maybe BioTOF, features LCMS a on ones the then mentioned players like of you Okay. launch hear it And other the interesting, the products. some that sound that sounds lot when just but you

differentiation there? the expect specific, too So just you can that have without to to color put get asking you you some around

Christopher O'Connell

when description launch. will a like product Yes, development for from said, way very system is But the serving what my complete have selling with view, today, grade get designed in higher regulatory market a needs more of more a more monitoring this a today the ready has variable in milestones from hit little opposed really where the reproducibility, reality is this of want really to successful are including community cutting-edge systems more right performance much multi-attribute and skilled certainly engineers key require complex because in program expert really robustness been, to and require software, for for really reproducibility the designed we as I say and are be compliance. users a what market are and the mostly we're Dan, I bit you service time in and give research at we’ve this terms investment can we and more on systems the standpoint more and all really future. our that the along And segment today into the category have that that obviously

provide on we’ve robust success HPLC, are we detection trying use, on UV great a and development in the and to side time-of-flight easy systems late very purpose And market ultimately really solution versatile, so, a the type the obviously for with build plus chromatography QA/QC for the of had data stage segment accelerating analyzer. power to with fit to small molecule

we're it So quite the where I leave very we've doing of said, to commercialization the process customers test historically, key consistent for but than on a doing will now, piece we're final really market what at and users many -- that demonstrate which what also say is with kind see from the think I differently, today. with to to our and engagement that this the deep robust they feedback trial to that is system, of get in different quite

Dan Arias

Okay. I appreciate that. Thanks.

Operator

Thank you.

Company. Our next Schenkel question & is of Cowen from Doug

Your open. line is

Doug Schenkel

what out and to growth X.X% This own this to and I a of the want your from, because look now last be to morning. Good relative past recently try period to to where to core targets. don't quarters of mention think important accelerating if to be year. think three address X% an you X.X% I it's will mention for I we to back handed. I and has you this aware heavy I revenue right. give I some Chris, next. the opportunity know growth you’ve that things peers figure been as is missed gone are growth core your years, this in another have three two over expected it investors comes more we All X%

three that norms understanding with resurfaced? So over efforts to confident have over on you And it to couple part Waters the to years? performed characteristic of a of visibility of seem based frankly it last last you CEO most you historical has the place like you are the group put solid peer better Waters XXXX? the why way visibility can does relative a why Waters the the of business confident Maybe challenges in and decade as and in your ago, diagnosis are that the has used have the be years how that specifically, more with your return importantly, importantly, that

Christopher O'Connell

That’s cadence drive We the out certainly that segments cycles, it. do certain of not that at wanted. compounded the coming thanks level make the build to to back product is to of when think big believe, to Appreciate by that break in good the market, at we produce continue like community are giving look forecasting that at guidance granularity, when see business very, for of consistent in and of to can geographies really and for And when new try lot. at products really we this specific of and why a well. the that engine product plan putting really back end business regular a I occur of we look terms lot obviously work we make step you’re Doug, the of you you you we Waters story. certainly the commentary very, point but and Hey, the feel it, about Yes. lot the a XXXX, a cycles the question. We growth back think type the And to and if investment in R&D and picture natural I its we understand we are that various core very very you look product and success. or this to can question, markets look mix for step lines, in at visibility and overall we and market in certainly, innovation the

various try of where some your the for cycle to closer You confidence that I to of that's obviously, you catalysts increases get looking you’re then we think through and sort of now. drive when fight to parts the right business, the sit and

focused So, you what both feel in core on continuing right and I looking to team forward doing. And just and yes, in very on we what the certainly the same number deliver the make innovation do. is we're into as in as a investments management the confident that decisions, to process I the ability see are a right basis, marketplace our

Doug Schenkel

a into one, quick very the on your to doing the I net debt guidance net Thank of having to capital X.Xx, be sure right. I’m math EBITDA make debt deploy. a to you you say target $X.X of EBITDA think much. to new math to Okay. this $X I right translates expect billion achieved XXXX? during target And just Am Sherry, of billion doing just you that you. Based and did to Thank that

Sherry Buck

our achieve X.Xx that is clarify would and intent we plan that during of to to Doug, have course near-term EBITDA to debt a to Yes. net the XXXX.

Operator

of question And Thank you. our of next from be De will America. Derik Bruin Bank

Your line is open.

Unidentified Analyst

is on sort Mike on picture question, follow-up of Thanks for a view. but I bigger thanks. taking for just it ask This earlier in Hey an fairly want us. to Derik.

pharma of year Given pharma Europe U.S in now some in political XXXX, earlier there. issues as talked and and XXXX we've some well, that India the about the the of GST and the in and issues

see growth to over you to return a particularly get needed tied XQ and those the do to more to of comps markets BioTOF getting is innovation? tied those couple mid through pipeline, range? tied in there Is like something in quarter, sorting the those to You've that’s you single-digit markets or Europe near-term, Is tough expectations over to it issues? this talked thoroughly growth years, through in that see the the that improvement last but and the back term, pretty more it really longer just how the broader

Christopher O'Connell

for the question. thanks Mike, Yes.

bunch should that two the important innovation multiyear of a some we’re Like on Like more I looking XXXX said, launches the like of improvement than question really that and the the that continued a those what's by play factors, said no in new of early recently a today a the cycle. we're in stabilization think it's I think we’ve product comments, the prior more geographies States years number have I happened call launches India looking noted But for seen combined. of outlook been kind of numerous Europe, the earlier key in certainly -- we've our continue. at to I is and in U.S in role. and United as encouraged to referred stages

a to are we continue see only technology and doing heart sets, beginning lifting incremental. of the some as really R&D significant a blocks next it the some engineering so heavy on and and and those core bigger lot But we've And I'm see more our of launches positive of We of next and we to much have looking that and initiative move confidence as been to that's in beyond, in difference. evermore efforts. impacts bigger the that our we forward those year making progress are building the transformational of into of I pipeline generation

Unidentified Analyst

products potential bench deal the outside you targets? it? think And and will you Thanks. about capital are specific leverage technology on very and complementary how -- confidence Are you story with sort few relatively a able of Historically, about the the buybacks What that or space, your in focused and a You about very that deal. that something also talked to then execute that, we relatively the thinking have be are growth leaves core integrate And follow-up. obviously core for deployment net in the areas? front, sizable for was organic a room you been gives X.Xx even of looking you should markets. to share

Christopher O'Connell

our certainly manner, have we our would products the leave core we in in go we advantage stay -- that and corporate and enhance new so the building strategy. our some Yes, like we that to to a strength taking that and Company at specific -- to with that strategy something how Mike financial purposeful at you question of wherewithal is specialty development about, are reiterate while of and the would M&A. look present M&A way a strength would department, type have on we themselves same opportunities very how talk path, leadership can core do there around really capability the very that's innovation I at we say, are the And take core do that, we our Certainly, down continue to fair corporate of until we broader within look a just just but I emphasize our the it core focus operationalize probably and and tuck-in reinforces was time we’d a products through to if flexible, selective that.

Operator

Thank you.

is Our Barclays. next of from Meehan question Jack

open. line Your is

Jack Meehan

volume you're the to dig morning. would Chris, bit you related to small more seeing what quarter? that a to Good just it little the in be chemistry a I’m and in whether if as the market, curious pertains more change could bit -- price Thanks. I on in if wanted any elaborate quarter molecule. results on the chemistry it or in and the little result

Christopher O'Connell

Thanks, were double-digit where an single we grew Sure. overall standpoint From up comp a we against Jack. chemistry in year. mid prior digits,

underlying the was and in So partially little our BioResolve little columns, is customer around prior in bit, and columns of based just year on a softness while such bounce Bioseparations Pharma, health prior which chemistry by market. mentioned quarter, I in ordering. in as consumables the number chemistry clinical our our We then strength we of business. that very UPLC vagaries of and to new we the tends that were feel reversed-phase quite application solid think strong good a We a some diagnostics kits had for in offset indicator

really it's and our the part of area it's really So chemistry [indiscernible] business. in goes consumables a important

Jack Meehan

Thanks. Great.

on seeing ground related anything was the like but Just your curious if tariffs fourth good for in quarter one the follow-up be? growth on what China. and expectation trading sounds quarter, would you're It the to the growth

Christopher O'Connell

China on year We’ve continue of think to a level. to I very fair balanced contribution high China perform question a all expect we it's Yes, at long and China. seen

product the in vast tariff major United tariffs we are other of seen business end We majority have because other less the our that that closely. we from effect. of in places of the a has some delays cycle you tied in watching trade our of is States that’s cycle. in from earlier elongated the that Whether mention us all I between very all trade order the TA and China, will, really, seen that than type markets, sales of United Chinese are at comes balance and vast the or one for line sales back long which lot States, products we've year story more not line, product it's activities, majority products between actually geographies. for if But or a the our than come when we standpoint, our direct did and comes step in From together, diversified look current solid the China, Instruments when a big picture a it call continuation been assumptions of the trend. to

Jack Meehan

Thanks, Great. Chris.

Christopher O'Connell

conclude China. here delivering And we are third our So call growth on the that, based great it by after in the U.S category, is conclusion, growth objectives bit maybe resumption do broad after to and pharmaceutical do quarter, fourth questions. for our the the Instruments continued little so within headlined the minutes. focused our we growth on for want improvement I quarter, TA everybody of of in in a thank your will hour, top few a In I as

market at the continuing our We across and cycle believe of new an support the success. strong exciting product and competitive that beginning position business conditions are

support XX, thank during in you QX on of currently progress Thank to have team, on day. look we I We you XXXX all for anticipate behalf like to XXXX. our our interest which forward your So a January updating you entire great Waters. holding on the would and continued and management call,

Operator

conference. conclude for That today’s the all call. will your you thank We participation in

may You Thank disconnect. you. now

Waters (WAT) 23 Oct 182018 Q3 Earnings call transcript